Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
Recruiting · NCT06575257 · Registry updated 2024-08-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 | 2024-08-28 | NCT06575257 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Xijing Hospital | 177 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The First Affillated Hospital, the Air Force Medical University | Xi’an | China | 1 |